Vertex Pharmaceuticals Incorporated – Cystic Fibrosis

Submitted By:
Published Date:
January 25, 2020

Access Program Information

To provide TEZ/IVA combination therapy to CF patients who are 12 years of age and older who
completed Vertex TEZ/IVA combination therapy clinical studies (NCT02565914 or NCT03150719).
To provide TEZ/IVA combination therapy to CF patients in critical need who are 12 years of
age and older, homozygous for F508del.

Rare Disease:
Cystic fibrosis